Combining tumor response and personalized risk assessment: Potential for adaptation of concurrent chemotherapy in locoregionally advanced nasopharyngeal carcinoma in the intensity-modulated radiotherapy era. (February 2021)

• Record Type: Journal Article
• Authors: Luo, Wei-Jie; Zou, Wen-Qing; Liang, Shao-Bo; Chen, Lei; Zhou, Guan-Qun; Peng, Hao; Li, Wen-Fei; Liu, Xu; Sun, Ying; Lin, Ai-Hua; Ma, Jun; Mao, Yan-Ping
• Is Part Of: Radiotherapy and oncology. Volume 155(2021)
• Page Start: 56
• Page End: 64
• Publication Date: 2021-02
• Subjects: AIC Akaike information criterion -- CCRT concurrent chemoradiotherapy -- CI confidence interval -- C-index concordance index -- CR complete response -- DFS disease-free survival -- DMFS distant metastasis-free survival -- EBV Epstein-Barr virus -- GP gemcitabine-cisplatin -- HR hazard ratio -- IC induction chemotherapy -- IMRT intensity-modulated radiotherapy -- LANPC locoregionally advanced nasopharyngeal carcinoma -- LRRFS locoregional relapse-free survival -- MRI magnetic resonance imaging -- MR-DWI magnetic resonance diffusion-weighted imaging -- NPC nasopharyngeal carcinoma -- OS overall survival -- PF cisplatin-5-fluorouracil -- PR partial response -- PTV planning target volume -- RT radiotherapy -- SD stable disease -- TP docetaxel-cisplatin -- TPF docetaxel-cisplatin-5-fluorouracil; Nasopharyngeal carcinoma -- Concurrent chemotherapy -- Induction chemotherapy -- Tumor response -- Risk factors -- Intensity-modulated radiotherapy; Oncology -- Periodicals; Radiotherapy -- Periodicals; Tumors -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- radiotherapy -- Periodicals; Radiotherapy -- Periodicals; Radiothérapie -- Périodiques; Cancérologie -- Périodiques; Tumeurs -- Périodiques; Electronic journals; 616.9940642
• DOI: 10.1016/j.radonc.2020.10.005
• Languages: English
• ISSNs: 0167-8140

Abstract

Highlights: CCRT after IC reduced hazard of failure and death in advanced NPC in the IMRT era. CCRT after IC did not benefit patients with unfavorable tumor response. CCRT after IC benefited patients with favorable tumor response. Unfavorable responders deserve intensification of concurrent chemotherapy. Omission of concurrent chemotherapy in low-risk favorable responders is reasonable. Abstract: Background and purpose: In the intensity-modulated radiotherapy (IMRT) era, the role of concurrent chemoradiotherapy (CCRT) after induction chemotherapy (IC) in locoregionally advanced nasopharyngeal carcinoma (LANPC) is undetermined, while concerns exist about CCRT-associated excessive toxicity. We aimed to combine tumor response and risk assessment to guide decisions about concurrent chemotherapy. Materials and methods: From April 2009 to December 2015, 744 LANPC patients treated with CCRT/IMRT after IC were included. Matching techniques were performed for treatment effect evaluation. Tumor response to IC was used for patient stratification. A nomogram was built based on multivariable Cox regression analysis to predict overall survival (OS). Results: After IC, 508 patients (68.3%) had favorable tumor response (complete or partial response), among whom IC + CCRT achieved significantly superior 5-year disease-free survival and OS than IC + IMRT (82.2% vs. 72.5%, P = 0.025; 89.2% vs. 79.9%, P = 0.025). However, no significant difference was found in patients with unfavorable response (both P > 0.05). For favorable responders, a nomogram was built integrating age, smoking, T category, N category, pretreatment Epstein-Barr virus DNA and treatment modality. The concordance index was 0.713 and calibration was good. The nomogram determined three risk groups with distinct OS. High-risk patients benefited from CCRT after IC regarding disease-free survival, OS and distant metastasis-free survival, whereas low- and intermediate-risk patients did not. Conclusions: For LANPC patients with unfavorable response to IC, subsequent CCRT seems inadequate, rendering intensification necessary. For favorable responders with low risk, IC + IMRT represents a reasonable de-intensification approach, although confirmation by prospective data is needed.